Adefovir
|
|
|
- CAS-Nr.
- 106941-25-7
- Englisch Name:
- Adefovir
- Synonyma:
- PMEA;GS-393;gs0393;Adefovi;ADEFOVIR;A Duff Vee;Adefovir98%;Adefovir API;adefovir ,97%;Adefovir(PMEA)
- CBNumber:
- CB2698137
- Summenformel:
- C8H12N5O4P
- Molgewicht:
- 273.19
- MOL-Datei:
- 106941-25-7.mol
|
Adefovir Eigenschaften
- Schmelzpunkt:
- >260°C
- Siedepunkt:
- 632.5±65.0 °C(Predicted)
- Dichte
- 1.88
- storage temp.
- -20°C
- Löslichkeit
- 0.1 M NaOH: ≥5mg/mL
- pka
- pKa1 2.0, pKa2 6.8(at 25℃)
- Aggregatzustand
- powder
- Farbe
- white to beige
- InChIKey
- SUPKOOSCJHTBAH-UHFFFAOYSA-N
- CAS Datenbank
- 106941-25-7(CAS DataBase Reference)
Sicherheit
- Risiko- und Sicherheitserklärung
- Gefahreninformationscode (GHS)
| Bildanzeige (GHS) |
|
| Alarmwort |
Achtung |
| Gefahrenhinweise |
| Code |
Gefahrenhinweise |
Gefahrenklasse |
Abteilung |
Alarmwort |
Symbol |
P-Code |
| H301 |
Giftig bei Verschlucken. |
Akute Toxizität oral |
Kategorie 3 |
Achtung |
![GHS hazard pictograms]() src="/GHS06.jpg" width="20" height="20" /> |
P264, P270, P301+P310, P321, P330,P405, P501 |
|
| Sicherheit |
| P301+P310 |
BEI VERSCHLUCKEN: Sofort GIFTINFORMATIONSZENTRUM/Arzt/... (geeignete Stelle für medizinische Notfallversorgung vom Hersteller/Lieferanten anzugeben) anrufen. |
|
Adefovir Chemische Eigenschaften,Einsatz,Produktion Methoden
Chemische Eigenschaften
Pale Brown Solid
Verwenden
Adefovir has been used to study its anti-retro viral effect on porcine endogenous retrovirus (PERV) activity.
Acquired resistance
It has a lower propensity to induce drug resistance than lamivudine.
Clinical trials of patients receiving 48 weeks of therapy
did not identify any cases of resistance. Longer courses
yield resistant strains of HBV with mutations in the DNA
polymerase gene; other rare variants of resistant strains have
been identified. Lamivudine-resistant strains of HBV retain
susceptibility to adefovir.
Pharmazeutische Anwendungen
A nucleotide analog of adenosine monophosphate, administered
orally as its prodrug, adefovir dipivoxil.
Pharmakokinetik
Oral absorption： c. 60%
C
max 10 mg/kg oral： 18.4 ng/mL
Plasma half-life： c. 7.5 h.
Volume of distribution： 392 mL/kg
Plasma protein binding： Not known
The prodrug is metabolized to adefovir, which is excreted by the kidneys and therefore requires dose adjustment in patients with impaired renal function. It does not induce cytochrome P
450 at standard doses and does not influence the metabolism or plasma concentrations of the other licensed medications used in the treatment of hepatitis B.
Clinical Use
Treatment of chronic hepatitis B virus infection in patients >12 years
of age
Nebenwirkungen
It is generally well tolerated, with headache, pharyngitis,
abdominal pain and peripheral neuropathy being the most
common side effects. Nephrotoxicity has been observed in
some patients, with those receiving higher doses and longer
courses of therapy at greater risk. Exacerbation of hepatitis
has been reported in patients immediately following discontinuation
of treatment. Most exacerbations occur within 12
weeks of stopping therapy, and elevations of alanine aminotransferase
(ALT) up to 10 times the upper limit of normal
can be observed in over 25% of patients. Lactic acidosis has
been reported in a few patients and is an indication for immediate
discontinuation.
Adefovir Upstream-Materialien And Downstream Produkte
Upstream-Materialien
Downstream Produkte
Adefovir Anbieter Lieferant Produzent Hersteller Vertrieb Händler.
Global( 403)Lieferanten
106941-25-7()Verwandte Suche:
- 2-(6-amino-9h-purin-
- Adefovir dipivox (PMEA)
- [[2-(6-AMino-9H-purin-9-yl)ethoxy]
Methyl]phosponic Acid
- P-[[2-(6-AMino-9H-purin-9-yl)ethoxy]Methyl]phosphonic Acid
- Adefovir(PMEA)
- Adefovir98%
- [({[2-(6-aMino-9H-purin-9-yl)ethoxy]Methyl}({[(2,2-diMethylpropanoyl)oxy]Methoxy})phosphoryl)oxy]Methyl 2,2-diMethylpropanoate
- A Duff Vee
- Adefovir API
- GS-393
- P-[[2-(6-Amino-9H-purin-9-yl)ethoxy]methyl]phosphonic acid, 9-(2-phosphonylmethoxyethyl)adenine
- 2-(6-Amino-9H-purin-9-yl)ethoxy]methylphosphonic acid Adefovir(PMEA)
- Adefovir Dipivoxil Impurity (Adefovir)
- 2-(6-amino-9h-purin-9-yl)ethoxy]methylphosphonic acid
- 9-[2-(PHOSPHONOMETHOXY)ETHYL]ADENINE
- 9-(2-PHOSPHONYL METHOXY ETHYL) ADENINE
- ADEFOVIR
- PMEA
- ((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)-phosphonicaci
- 9-[2-(6-Amino-9H-purin-9-yl)ethoxy]methylphosphonicacid
- [[2-(6-amino-9H-purin-9-yl) ethoxy] methyl] phosphonic acid (PMEA)
- PMEA([[2-(6-amino-9H-purin-9-yl)
- 9-[2- (phosphonomethoxy) ethyl] adenine, alternate name adefovir[PMEA]
- [2-(6-Amino-9H-purine-9-yl)ethoxymethyl]phosphonic acid
- Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]- (9CI)
- 9-[2-(6-Amino-9H-purin-9-yl)et
- Adefovir & Adefovir Dipivoxil
- gs0393
- adefovir ,97%
- 9-[2-[bis(pivaloyloxymethoxy)phosphorylmethoxyl]ethyl]adenine
- 9-(2-Phosphonomethoxy Etheyl) Adenine
- 9-(2-PHOSPHORYL METHOXYL ETHYL) ADENINE
- 9-(2-(2-phosphoromethoxy)ethyl adenine (PMEA)
- Adefovir dipivoxil intermediate B
- 2-(6-AMINO-9H-OUR IN-9-YL)ETHOXY]METHYLPHOSPHONIC ACID
- 9-[2-phosphonylmethoxyethyl]ad
- Adefovir,9-[2-phosphonylmethoxyethyl]adenine
- 9-(2-PHOSPHONYLMETHOXYETHYL)ADENINE(ADEFOVIR)
- [[2-(6-Amino-9H-purin-9-yl)ethoxy]methyl]phosponicAcid,PMEA,GS-393,
- treatment Adefovir
- Tenofovir Desmethyl Impurity
- Adefovi
- Phosphonic acid, P-[[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]-
- Phosphonic acid, [[2-(6-amino-9H-purin-9-yl)ethoxy]methyl]-
- Adefovir USP/EP/BP
- Adefovir (GS-0393)
- AdefovirQ: What is
Adefovir Q: What is the CAS Number of
Adefovir Q: What is the storage condition of
Adefovir Q: What are the applications of
Adefovir
- 3-Di-o-tolylguanidine
- 2-(6-Aminopurin-9-yl)ethoxymethylphosphonic acid
- 106941-25-7
- C8H12N5O4P
- C8H14N5O4P
- C8H13N5O4P
- Other Products
- Aromatics
- Heterocycles
- Intermediates & Fine Chemicals
- Pharmaceuticals
